Project: Artificial-intelligence-based end-to-end prediction of cancer immunotherapy response

Acronym	TANGERINE (Reference Number: TRANSCAN2021-071)
Project Topic	Background Cancer immunotherapy with immune checkpoint inhibitors (ICIs) is widely used in multiple cancer types, with proven benefits. However, response is not guaranteed, difficult to predict, and serious toxicity may occur. Predictive biomarkers for ICIs response exist, but only few of them are clinically used because they require tissue samples, are costly and increase turnaround time. Thus, there is an urgent clinical need to predict response to ICIs at patient’s level. Aims TANGERINE partners have developed artificial intelligence (AI)-based histology image analysis and computed tomography (CT)-based radiomics for predicting immune features related to ICIs response. We propose to a) expand and combine them to develop and validate an end-to-end open AI tool to predict response and toxicity to ICIs; and b) identify cellular structures and image patterns associated with ICIs response that explain model predictions. Methods Digital images of tumour histopathology slides and CT scans will be retrieved, linked to clinical outcomes data and anonymized for analysis. An initial retrospective (2017-21) data retrieval from 1800 patients at 6 centres will continue with a prospective recruitment of 600 more to validate models. Patients that received ICls as first line for any tumour will be included and response recorded according to iRECIST. Radiomics and deep convolutional neural networks will be used. Model explainability will use spatial transcriptomics data on a subset of 30 patients. At analysis, homogenous subgroups will be considered, as gender and ethnicity. Expected results and potential impact TANGERINE will provide a public-available, non-invasive, low-cost tool based on routinely available images and clinical data to accurately predict ICI response and toxicity. The explanatory module might identify new patients on which ICI may be beneficial. The transnational collaboration will provide patients with enough variability to build generalizable models.
Network	TRANSCAN-3
Call	1st TRANSCAN-3 Joint Call 2021

Project partner

Number	Name	Role	Country
1	Bellvitge Biomedical Research Institute	Coordinator	Spain
2	University Hospital Aachen	Partner	Germany
3	Henri-Mondor University Hospital	Partner	France
4	Technion & Carmel Medical Center	Partner	Israel
5	Fundación Hospital Universitario Vall d’Hebron	Partner	Spain
6	The Oncology Institute "Prof Dr. Ion Chiricuta"	Partner	Romania